Boston Scientific Lays Out Near-Term Growth Plan
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific’s ongoing effort to reorganize and recharge its product pipeline and reduce manufacturing costs will restore higher revenue growth over the next few years, executives said during a Nov. 19 day-long investor presentation.
You may also be interested in...
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011
For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.
New Products In Brief
Boston Scientific’s next-gen defibrillators
New Products In Brief
Boston Scientific’s next-gen defibrillators